UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Journal of hepatology, 2019-05, Vol.70 (5), p.1019-1023

2019

Volltextzugriff (PDF)

Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection

World journal of gastroenterology : WJG, 2014-08, Vol.20 (31), p.10984-10993

2014

Volltextzugriff (PDF)

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

Hepatology communications, 2022-09, Vol.6 (9), p.2488-2495

2022

Volltextzugriff (PDF)

Chronic hepatitis C： Treat or wait？ Medical decision making in clinical practice

World journal of gastroenterology : WJG, 2012-03, Vol.18 (12), p.1339-1347

Claus Niederau Dietrich Huppe EImar Zehnter Bernd Moiler, Renate Heyne Stefan Christensen Rainer Waft Arno Theilmeier Ulrich Alshuth Stefan Mauss

2012

Volltextzugriff (PDF)

Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir

Hepatology (Baltimore, Md.), 2014-01, Vol.59 (1), p.46-48

2014

Volltextzugriff (PDF)

A not so easy genotype—striking regional differences in SOF/RBV treatment responses in HCV GT2

Liver international, 2017-08, Vol.37 (8), p.1253-1254

2017

Volltextzugriff (PDF)

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

Journal of hepatology, 2017-11, Vol.67 (5), p.918-924

2017

Volltextzugriff (PDF)

HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe

Journal of hepatology, 2017-02, Vol.66 (2), p.282-287

2017

Volltextzugriff (PDF)

Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010–2015

Journal of hepatology, 2017-07, Vol.67 (1), p.15-22

2017

Volltextzugriff (PDF)

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

Journal of hepatology, 2018-04, Vol.68 (4), p.663-671

2018

Volltextzugriff (PDF)

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry

Liver international, 2021-05, Vol.41 (5), p.949-955

2021

Volltextzugriff (PDF)

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

Liver international, 2020-03, Vol.40 (3), p.539-548

2020

Volltextzugriff (PDF)

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)

Journal of viral hepatitis, 2021-10, Vol.28 (10), p.1474-1483

2021

Volltextzugriff (PDF)

Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B

Journal of hepatology, 2011-12, Vol.55 (6), p.1235-1240

2011

Volltextzugriff (PDF)

Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection

Hepatology (Baltimore, Md.), 2004-12, Vol.40 (6), p.1421-1425

2004

Volltextzugriff (PDF)

Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)

Zeitschrift fur Gastroenterologie, 2023-05, Vol.61 (5), p.489-503

2023

Volltextzugriff (PDF)

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial

Hepatology (Baltimore, Md.), 2013-06, Vol.57 (6), p.2143-2154

2013

Volltextzugriff (PDF)

Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”

Journal of hepatology, 2017-08, Vol.67 (2), p.420-422

2017

Volltextzugriff (PDF)

Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study

Clinical gastroenterology and hepatology, 2023-03, Vol.21 (3), p.713-722.e3

2023

Volltextzugriff (PDF)

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Journal of hepatology, 2020-03, Vol.72 (3), p.431-440

2020

Volltextzugriff (PDF)

Treatment of viral hepatitis in HIV–coinfected patients–adverse events and their management

Journal of hepatology, 2006, Vol.44 (1 Suppl), p.S114-S118

Mauss, Stefan

2006

Volltextzugriff (PDF)

A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance

Hepatology (Baltimore, Md.), 2004-07, Vol.40 (1), p.120-124

2004

Volltextzugriff (PDF)

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials

Liver international, 2017-02, Vol.37 (2), p.205-211

2017

Volltextzugriff (PDF)

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders

Journal of hepatology, 2015-07, Vol.63 (1), p.30-37

2015

Volltextzugriff (PDF)

1 – 25 von 45

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

KollektionTaylor & Francis:Master (3349 titles)

SpracheDeutsch

ThemaGastroenterology & Hepatology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(42)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(45)

Sprache

Englisch
(45)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(45)
Science & Technology
(45)
Humans
(32)
Male
(24)
Female
(23)
Hepatitis C
(23)
Middle Aged
(22)
Adult
(20)
Antiviral Agents - Therapeutic Use
(18)
Hepatitis
(15)
Hepatitis C, Chronic - Drug Therapy
(15)
Drug Therapy, Combination
(12)
Patients
(12)
Infectious Diseases
(10)
Treatment Outcome
(10)
Antiviral Agents
(9)
Hepacivirus - Genetics
(9)
Hiv
(9)
Cirrhosis
(8)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Retreatment of patients who failed glecaprevir/pibrentasvir treatment for hepatitis C virus infection

Age-related differences in response to peginterferon alfa-2a/ribavirin in patients with chronic hepatitis C infection

Elevated liver enzymes predict morbidity and mortality despite antiviral cure in patients with chronic hepatitis C: Data from the German Hepatitis C‐Registry

Chronic hepatitis C： Treat or wait？ Medical decision making in clinical practice

Renal impairment is frequent in chronic hepatitis C patients under triple therapy with telaprevir or boceprevir

A not so easy genotype—striking regional differences in SOF/RBV treatment responses in HCV GT2

Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study

HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe

Real-world treatment for chronic hepatitis C infection in Germany: Analyses from drug prescription data, 2010–2015

Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C

Glecaprevir/pibrentasvir is safe and effective in hepatitis C patients with cirrhosis: Real‐world data from the German Hepatitis C‐Registry

Baseline risk factors determine lack of biochemical response after SVR in chronic hepatitis C patients treated with DAAs

The changing characteristics of patients infected with chronic hepatitis C virus from 2014 to 2019: Real‐world data from the German Hepatitis C‐Registry (DHC‐R)

Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B

Comparison of adefovir and tenofovir in the treatment of lamivudine‐resistant hepatitis B virus infection

Real-world experience for the outcomes and costs of treating hepatitis C patients: Results from the German Hepatitis C-Registry (DHC-R)

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial

Reply to: “Negotiating better discounts for DAA therapy is critical to achieve HCV elimination by 2030”

Screening HIV Patients at Risk for NAFLD Using MRI-PDFF and Transient Elastography: A European Multicenter Prospective Study

Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy—Results from the German Hepatitis C‐Registry

Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial

Treatment of viral hepatitis in HIV–coinfected patients–adverse events and their management

A prospective controlled study of interferon‐based therapy of chronic hepatitis C in patients on methadone maintenance

Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials

Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders

Aktive Filter

Suchergebnisse filtern